Hot flashes, night sweats, insomnia – OB-GYNS set new rules for menopause treatment

Read the original at NPR ↗
Cite

Firth, S. (2026, October 16). Hot flashes, night sweats, insomnia – OB-GYNS set new rules for menopause treatment. NPR. https://www.npr.org/2026/10/16/nx-s1-6005201/health-treatment-menopause-hot-flash-night-sweats-insomnia

Dated from the outlet's own feed. Check the original for its byline.

NPR · collected 2026-10-16 · by Shannon Firth

Quick Summary

The American College of Obstetricians and Gynecologists (ACOG) has updated its guidelines for treating menopause symptoms, the first update since 2014. The new recommendations suggest using hormone replacement therapy along with certain antidepressants and nonhormonal medicines like Veozah and Lynkuet to address hot flashes, insomnia, and mood swings. ACOG emphasizes that hormone therapy is now considered safe for newly menopausal women under age 60 or within 10 years of their final period due to more recent evidence supporting its safety and efficacy.
Written locally by qwen2.5:14b on 2026-10-16, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

The American College of Obstetricians and Gynecologists (ACOG) has updated its guidelines for treating menopause symptoms for the first time since 2014. The new recommendations include hormone replacement therapy alongside nonhormonal options like the drugs Veozah (fezolinetant), approved in 2023, and Lynkuet (elinzanetant), approved in 2025. Dr. Catherine Cansino, chair of ACOG's Committee on Clinical Practice Guidelines, emphasized that the safety of hormone replacement therapy is now well-established, contrary to earlier concerns raised by the Women's Health Initiative in 2002 which suggested it increased risks for heart disease, breast cancer, stroke, and pulmonary embolism. The updated guidelines aim to provide a more personalized approach to treating symptoms such as hot flashes, night sweats, and insomnia.

Written for “Menopause Treatment Guidelines Updated” on 2026-10-16, grounded in this article and the 0 other(s) covering the same event.

Story

📰 Menopause Treatment Guidelines Updated
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
41
sentences that state something as happening or true
Uncertain
15%
6 of 41 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
60/100
NPR's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-16 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

NPR · 737 article(s) · 3 correction(s) detected
Running correction rate · 3 correction(s)

Who wrote this

Shannon Firth
1 article(s) here · 1 carrying a prediction
🔮 Still, patients may have their own preferences and goals, Cansino said.
The only article under this byline in the corpus.

Topics

ACOG Committee on Clinical Practice Guidelines Veozah the American College of Obstetricians and Gynecologists the Women's Health Initiative

Subjects

ACOG ORG · 4× Cansino PERSON · 4× Catherine Cansino PERSON · 1× Committee on Clinical Practice Guidelines ORG · 1× Robert Kauffman, PERSON · 1× the American College of Obstetricians and Gynecologists ORG · 1× the Food and Drug Administration ORG · 1× the Women's Health Initiative ORG · 1×

Narrative

In addition to hormone replacement therapy, the guidelines highlight new nonhormonal options for treating menopausal symptoms, including the drug fezolinetant, brand name Veozah, which the Food and Drug Administration approved to treat hot flashes in 2023 and elinzanetant, brand name Lynkuet, which was approved in 2025.
framing: assertive · carried by 1 article(s) · first seen 2026-10-16
🔮 Still, patients may have their own preferences and goals, Cansino said.

Claims (41 extracted, 6 hedged)

Hot flashes, night sweats, insomnia – OB-GYNS set new rules for menopause treatment asserted
GYNS → set → treatment
For the first time since 2014, the American College of Obstetricians and Gynecologists has updated its guidelines for the treatment of symptoms commonly associated with menopause. asserted
College → update → menopause
The doctor's group, known as ACOG, recommends hormone replacement therapy alongside certain antidepressants, nonhormonal medicines, and other treatments to address symptoms like hot flashes, insomnia and mood swings. asserted
group → know → flashes
"What's changing is the breadth of options that we now have … asserted
we → change → that
And the benefit of that is that we are better equipped to be able to take an individualized approach for patients," said Catherine Cansino, MD, MPH, an obstetrician/gynecologist, chair of ACOG's Committee on Clinical Practice Guidelines and co-author of the new guidance. asserted
Cansino → equip → guidance
The guidance, released Thursday, focuses on specific menopausal symptoms and underscores that the safety of hormone replacement therapy is now "well-established," Cansino said. asserted
Cansino → release → therapy
In 2002, the Women's Health Initiative suggested that hormone replacement therapy increased the risk of heart disease, breast cancer, stroke and pulmonary embolism. uncertain
therapy → suggest → disease
However, as researchers revisited that data years later, they noticed certain limitations, (including that a majority of participants were 60 years or older) making it difficult to generalize the findings to younger women experiencing menopause or perimenopause. asserted
it → revisit → menopause
With more and better quality studies, physicians are able to review the evidence and make better-informed recommendations, Cansino said. asserted
Cansino → review → recommendations
"Hormone therapy is probably the best option for symptomatic, newly menopausal women within 10 years of the final menstrual period or before the age of 60," said Robert Kauffman, MD, MSCP, a co-author of the guidelines, during a press briefing on Thursday. asserted
Kauffman → say → Thursday
In addition to hormone replacement therapy, the guidelines highlight new nonhormonal options for treating menopausal symptoms, including the drug fezolinetant, brand name Veozah, which the Food and Drug Administration approved to treat hot flashes in 2023 and elinzanetant, brand name Lynkuet, which was approved in 2025. asserted
which → highlight → 2025
"What's so exciting about these treatment options is they were specifically studied based on the understanding that we have of the physiology of thermoregulation and sleep," Cansino said. asserted
Cansino → study → thermoregulation
The medications work by blocking certain chemical messengers in the part of the brain that regulates body temperature and manages sleep/wake cycles, according to the guidance. uncertain
that → work → guidance
About 2 million women begin menopause each year. asserted
women → begin → menopause
The average age of a woman experiencing menopause is 49.9 years, according to the guidelines. uncertain
age → experience → guidelines
However, symptoms of menopause can begin years before a woman's final menstrual period. asserted
symptoms → begin → period
The new recommendations support the use of systemic hormone replacement therapy, or HRT, with a combination of estrogen and progestogen in women with a uterus who have no contraindications to hormones. asserted
who → support → hormones
Reasons to avoid hormone therapy include undiagnosed abnormal genital bleeding, and current or past histories of certain gynecologic cancers, blood clots, stroke, heart attack, liver disease or a known or suspected pregnancy. asserted
Reasons → avoid → cancers
The reason progestogen is recommended in women with a uterus is because estrogen can stimulate growth of the uterine lining and increase the risk of endometrial cancer. asserted
estrogen → recommend → cancer
Progestogen therapy helps mitigate that risk, Cansino explained. asserted
Cansino → help → risk
Around half a million women have hysterectomies each year, and for women without a uterus, ACOG recommends estrogen alone. asserted
ACOG → have → estrogen
As an alternative to estrogen-progestogen therapy, ACOG also recommends a pill, sold under the brand name Duavee, that combines estrogen and a drug called bazedoxifene. asserted
that → recommend → estrogen
Bazedoxifene is a "selective estrogen receptor modulator," which blocks the estrogen from working in certain areas of the body, such as breast tissue, while mimicking estrogen's benefit for bone density, for instance. asserted
which → block → instance
Another drug recommended in the new guideline is gabapentin, an anticonvulsant typically used to treat seizures. asserted
drug → recommend → seizures
It can also manage menopause symptoms for people who can't tolerate hormones or the other new medicines. asserted
who → manage → hormones
Cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture can all improve some symptoms, ACOG says, however the guidelines also note that the evidence for these interventions is weaker than the evidence for HRT. asserted
evidence → base → HRT
Still, patients may have their own preferences and goals, Cansino said. uncertain
Cansino → have → preferences
"I live in California, and I have a practice where many patients don't necessarily want pharmacologic therapy," Cansino said. asserted
Cansino → live → therapy
So, she tends to have a lot of conversations about non-pharmacologic treatment options with her patients. asserted
she → tend → patients
"A healthy diet and regular physical exercise is going to go a long way. asserted
diet → go → way
So let's start with that," and then discuss what other interventions to add to the regimen, she said. asserted
she → let → regimen
Asked, in a follow-up email, whether Cansino recommended one medication or tool over another, she warned against "over-simplifying treatment based on tiers. asserted
she → ask → tiers
Just like with contraception, she noted that patients may choose a certain method, knowing that it's less effective. uncertain
it → note → method
"As long as they understand the pros and cons, such a decision is perfectly OK." asserted
decision → understand → pros
Meanwhile, demand for HRT is already rising. asserted
demand → rise → HRT
Last year, the FDA scrapped the "black-box warning" on labels for certain estrogen therapies. asserted
FDA → scrap → therapies
In recent months, estrogen products like transdermal patches have been hard for pharmacies to keep in stock. asserted
pharmacies → keep → stock
"I think the shortage of transdermal estrogen therapy highlights the fact that we have all of this attention about hormone therapy, and not necessarily enough about other treatment options," Cansino told NPR. asserted
Cansino → think → NPR
She also stressed the need for patients to talk to trusted clinicians about the pros and cons of treatments and to avoid having "tunnel vision" about a single option. asserted
patients → stress → option
The level of care that OB/GYNs provide by helping individual patients find the right treatment is one of the most important aspects of the new guidance, Cansino said. asserted
Cansino → provide → guidance
…and 1 more, not listed.
💬Give feedback
🕘History 🎫Support